Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAZNI: Tazemetostat With Nivolumab and Ipilimumab for INI1-Negative or SMARCA4-Deficient Tumors
NCT05407441Phase 2Active, not recruiting
- Start
- Aug 2023
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tazemetostat in Atypical teratoid rhabdoid tumor (ATRT), malignant rhabdoid tumor (MRT), Rhabdoid Tumor of the Kidney (RTK), epithelioid sarcoma (ES), chordoma. Started Aug 2023; status: active, not recruiting.
02
Drugs
tazemetostat
03
Conditions
Atypical teratoid rhabdoid tumor (ATRT)malignant rhabdoid tumor (MRT)Rhabdoid Tumor of the Kidney (RTK)epithelioid sarcoma (ES)chordoma
Beyond the preview
Go deeper on NCT05407441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05407441.